Spondyloarthritis & psoriatic arthritis
Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study
Authors' conclusion
Apremilast improved inflammation in joints and entheses on assessment of MRI measures in the hand and the whole body.
Study context
- Population
- Adults with PsA of 3 months to 5 years duration, active disease with ≥3 swollen and ≥3 tender joints with hand involvement and ≥1 active enthesitis site; no prior bDMARD or >2 csDMARDs; 29 sites in ten countries122 treated and analysed
- Participants
- 123 adults
- Outcome
- Change in composite hand inflammation score (bone marrow oedema, synovitis, tenosynovitis) by PsAMRIS
- Follow-up
- Week 24
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Change in composite inflammation score of bone marrow oedema, synovitis and tenosynovitis in the hand (PsAMRIS)
Least squares mean change from baseline to week 24 in the PsAMRIS composite inflammation score
−2.32
95% CI −4.73 to 0.09
Safety
At least one treatment-emergent adverse event
- Patients with at least one treatment-emergent adverse event, 95 (78%) of 122
Severe treatment-emergent adverse event
- Patients with a severe treatment-emergent adverse event, Six (5%)
Serious treatment-emergent adverse event
- Patients with a serious treatment-emergent adverse event, six (5%)
- No serious treatment-emergent adverse events were considered to be related to apremilast
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study. Lancet Rheumatol. Published 30 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →